{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:10:28Z","timestamp":1791159028055,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","content-domain":{"domain":["journals.elsevierhealth.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.ijantimicag.2013.05.007","type":"journal-article","created":{"date-parts":[[2013,7,7]],"date-time":"2013-07-07T03:31:19Z","timestamp":1373167879000},"page":"256-261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections"],"prefix":"10.1016","volume":"42","author":[{"given":"C.","family":"Magis-Escurra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.W.","family":"Alffenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Hoefnagels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.N.R.","family":"Dekhuijzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Boeree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"van Ingen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.E.","family":"Aarnoutse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2013.05.007_bib0005","first-page":"665","article-title":"Pulmonary non-tuberculous mycobacterial infections","volume":"14","author":"Daley","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijantimicag.2013.05.007_bib0010","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2013.05.007_bib0015","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1136\/thx.2008.110957","article-title":"Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen\u2013Arnhem region, The Netherlands","volume":"64","author":"van Ingen","year":"2009","journal-title":"Thorax"},{"key":"10.1016\/j.ijantimicag.2013.05.007_bib0020","first-page":"1176","article-title":"The changing pattern of clinical Mycobacterium avium isolation in The Netherlands","volume":"14","author":"van Ingen","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijantimicag.2013.05.007_bib0025","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1164\/rccm.200509-1531OC","article-title":"Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease","volume":"173","author":"Lam","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2013.05.007_bib0030","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.pupt.2010.06.002","article-title":"The therapeutic approach to non-tuberculous mycobacterial infection of the lung","volume":"23","author":"McGrath","year":"2010","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2013.05.007_bib0035","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/infdis\/171.3.747","article-title":"Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium\u2013M. intracellulare infection","volume":"171","author":"Wallace","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.05.007_bib0040","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1300\/J100v02n02_02","article-title":"Evaluation of the drug interaction between clarithromycin and rifampin","volume":"2","author":"Peloquin","year":"1996","journal-title":"J Infect Dis Pharmacother"},{"key":"10.1016\/j.ijantimicag.2013.05.007_bib0045","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1128\/AAC.00099-10","article-title":"Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection","volume":"54","author":"Alffenaar","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.007_bib0050","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1164\/rccm.201204-0682OC","article-title":"The pharmacokinetics of pulmonary Mycobacterium avium complex disease treatment and its relation to drug susceptibility testing results","volume":"186","author":"van Ingen","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2013.05.007_bib0055","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ijantimicag.2011.09.019","article-title":"Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease","volume":"39","author":"van Ingen","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2013.05.007_bib0060","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2165\/00003088-198409060-00003","article-title":"Clinical pharmacokinetics of the antituberculosis drugs","volume":"9","author":"Holdiness","year":"1984","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2013.05.007_bib0065","series-title":"Drug susceptibility in the chemotherapy of mycobacterial infections","first-page":"59","article-title":"Antituberculosis drugs: pharmacokinetics","author":"Peloquin","year":"1991"},{"key":"10.1016\/j.ijantimicag.2013.05.007_bib0070","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1093\/infdis\/jir658","article-title":"Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability","volume":"204","author":"Srivastava","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.05.007_bib0075","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/cid\/cis353","article-title":"Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy","volume":"55","author":"Pasipanodya","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.05.007_bib0080","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pupt.2011.12.001","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis patients","volume":"25","author":"Magis-Escurra","year":"2012","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2013.05.007_bib0085","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1128\/AAC.01550-06","article-title":"Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients","volume":"51","author":"Ruslami","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.007_bib0090","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1086\/521894","article-title":"Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis","volume":"45","author":"Nijland","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2013.05.007_bib0095","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/j.jchromb.2009.04.038","article-title":"Simultaneous determination of clarithromycin, rifampicin and their main metabolites in human plasma by liquid chromatography\u2013tandem mass spectrometry","volume":"877","author":"de Velde","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.ijantimicag.2013.05.007_bib0100","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.2165\/00003495-200262150-00001","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis","volume":"62","author":"Peloquin","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2013.05.007_bib0105","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00003088-199937050-00003","article-title":"Clinical pharmacokinetics of clarithromycin","volume":"37","author":"Rodvold","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2013.05.007_bib0110","unstructured":"Zithromax 2005. Utrecht, The Netherlands: College ter Beoordeling van Geneesmiddelen MEB; 23 January 2006. Report No. IPD#177 10 December 1999."},{"key":"10.1016\/j.ijantimicag.2013.05.007_bib0115","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1183\/09031936.00176610","article-title":"Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience","volume":"38","author":"Pranger","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2013.05.007_bib0120","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1128\/AAC.36.10.2104","article-title":"Activities of WIN-57273, minocycline, clarithromycin, and 14-hydroxy-clarithromycin against Mycobacterium avium complex in human macrophages","volume":"36","author":"Cohen","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.05.007_bib0125","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1124\/dmd.111.039206","article-title":"Oral absorption of clarithromycin is nearly abolished by chronic comedication of rifampicin in foals","volume":"39","author":"Peters","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ijantimicag.2013.05.007_bib0130","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijantimicag.2009.09.023","article-title":"In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The Netherlands","volume":"35","author":"van Ingen","year":"2010","journal-title":"Int J Antimicrob Agents"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857913001933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857913001933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,14]],"date-time":"2018-10-14T19:50:10Z","timestamp":1539546610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857913001933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0924857913001933"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.05.007","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}